[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with Mutation--Review].

mutation is the main mechanism of resistance to the first and second generation tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML). Ponatinib as the third generation TKI has been found that can significantly improve the prognosis of CML patients with mutation. However, the latest report has discovered that the compound mutant is even resistant to ponatinib, which aroused the enthusiasm of research on the mechanism of CML resistance and targeted therapy once again. Previous studies have shown that TKI combined with other targeted drugs is effective to CML patients with drug resistance or relapse due to mutation. The latest research has found that the allosteric inhibitor asciminib combined with TKI therapy is equally effective to CML patients with compound mutant, but the specific mechanism is not yet clarified. This review will focus on the latest research progress of therapy for CML with mutation, hoping to provide reference for researching new drugs and improve therapy for treating CML with mutation.